Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in OncologyOpen Access

Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

KLKatherine E. LakeMJMeredith JacksonSHStephen S. Hull

Discussion

Loading...

Member takes

Overview

Retrospective review shows 90% response rate in indolent B-cell non-Hodgkin lymphomas, indicating effective dual therapy.

Key Points

  • The combination of rituximab and ultra-low-dose radiation therapy shows a 90% response rate in patients.
  • In-field progression-free survival at 2 years reached 91%, highlighting effective local control.
  • Response was measured using PET/CT, ensuring accurate evaluation of treatment efficacy.
  • No major toxicities were reported, suggesting this approach minimizes side effects compared to traditional treatments.

Cite This Study

Lake et al. (2025) studied this question.

synapsesocial.com/papers/68c23e4fb210217d64791ab9https://doi.org/10.3389/fonc.2025.1617087
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Role of Radiotherapy After Full Course of Chemotherapy in the Treatment of Diffuse Large B‐Cell Lymphoma: A Systematic Review and Meta‐Analysis2025
  2. 2Rituximab plus lenalidomide (R²) versus standard therapies in follicular lymphoma: A systematic review and meta-analysis of randomized controlled trials2025
  3. 3Lenalidomide–rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach2025 · 1 citations
  4. 4Short-term follow-up results of ultra-low-dose radiotherapy for indolent B-cell lymphoma2025
  5. 5Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial2025